Article
Buying Tyme: Syros inks $190M merger, Flagship-backed financing to extend cash runway into 2025
Rating:
0.0
Views:
42
Likes:
1
Library:
1
Syros Pharmaceuticals has bought itself that most prized of assets in today's biotech market: time. | Syros Pharmaceuticals has bought itself that most prized of assets in today's biotech market: time. By merging with the floundering Tyme Technologies and tapping investors including Flagship Pioneering, the gene expression biotech has extended its cash runway out into 2025.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value